Automated Staining Platform for Immunohistochemistry and In Situ Hybridization

用于免疫组织化学和原位杂交的自动化染色平台

基本信息

  • 批准号:
    10177257
  • 负责人:
  • 金额:
    $ 22.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT The Ventana Discovery Ultra is an automated stainer for immunohistochemistry (IHC) and in situ hybridization (ISH). The Confocal Microscopy and Image Analysis Core (CMIAC) at the Tulane National Primate Center (TNPRC) has over 30 years of combined experience performing IHC and ISH in nonhuman primate (NHP) tissues. Over the years, IHC and ISH have become fundamental to NIH-funded research at the TNPRC and are widely used by both intramural and extramural investigators. IHC and ISH staining at the TNPRC is currently performed manually by technicians with years of experience. In recent years, the CMIAC has acquired digital pathology and computer-based analyses that allow for the sensitive detection and quantification of IHC and ISH staining. These technological advancements have led to a need for highly reproducible IHC and ISH staining not achievable with the current manual methods. To address this need, nine NIH-funded principal investigators with a total of $19M per year in NIH funding have requested to be major users of the proposed Ventana Discovery Ultra because of its ability to improve the rigor and reproducibility of their IHC and ISH data. The Ventana Discovery Ultra is capable of completing the entire staining process from baking through secondary antibody application, preventing the need for manual intervention at any stage of the process. Multiplex staining protocols that require multiple rounds of primary and secondary antibody staining can also be performed without manual intervention. The Ventana Discovery Ultra is uniquely designed for research, allowing customization of each step of the staining protocol. This is ideal for the development of novel staining protocols, a necessity in NHP research which often requires the optimization of antibodies primarily generated for use in other species (mouse and human). Further, the Ventana Discovery Ultra accepts antibodies, probes, and reagents from third-party vendors, another important feature for the continued use of our extensive catalog of NHP-validated antibodies. In addition, the Ventana Discovery Ultra is one of the few automated stainers capable of performing ISH with signal amplification (RNAScope, ACDbio), a new leading-edge staining technique that is rapidly gaining popularity. This state-of-the-art functionality is necessary to meet the anticipated needs of our users for years to come. The Ventana Discovery Ultra also comes equipped with 30 individual slide bays allowing for the simultaneous staining of 30 unique protocols. This increases efficiency, enhances turnaround time, and facilitates the completion of multiple service requests for a Core laboratory that accommodates 25 investigators on an annual basis.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Blair其他文献

Robert Blair的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Blair', 18)}}的其他基金

The impact of vaping aerosol exposure on innate pulmonary defense mechanisms in nonhuman primates
电子烟气溶胶暴露对非人灵长类动物先天肺防御机制的影响
  • 批准号:
    10594499
  • 财政年份:
    2022
  • 资助金额:
    $ 22.75万
  • 项目类别:
The impact of vaping aerosol exposure on innate pulmonary defense mechanisms in nonhuman primates
电子烟气溶胶暴露对非人灵长类动物先天肺防御机制的影响
  • 批准号:
    10428016
  • 财政年份:
    2022
  • 资助金额:
    $ 22.75万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 22.75万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 22.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了